Jim O’Connor Named General Counsel and Senior Vice President, Strategic Development Announces Renovia

HRS Scientific Sessions: Boston Scientific LBCT

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

What are the Most Commonly Performed Surgeries?

Whether you are trying to learn more about a surgery you are planning to have or find out what the most common procedures are, this list is here for you. Read more.

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

Today Renovia announced the immediate appointment of  Jim O’Connor as General Counsel & Senior Vice President, Strategic Development.

Mr. O’Connor joined Renovia as General Counsel in February 2018 and since then has led the company’s legal, compliance, quality and regulatory functions. In his new role, Mr. O’Connor’s responsibilities will expand to include corporate business development, manufacturing, program management and overseeing Renovia’s finance team. He will also assist in identifying and implementing programs to improve organizational efficiency and execution.

“Jim has shown remarkable judgment and versatility, and has become a key cross-functional leader,” said Marc Beer, Co-Founder, Chairman and Chief Executive Officer of Renovia. “In his Strategic Development role, Jim will partner with the entire Renovia team to develop and implement strategies to maximize return on investments across our technology portfolio. As Renovia continues its growth and prepares for commercial launch of our next-generation digital therapeutics, he will also help drive potential business development and partnership opportunities.”

“I am so fortunate to work with the outstanding, mission-driven teams across Renovia and genuinely honored to take on this broader leadership role,” stated Mr. O’Connor. “I look forward to working closely with Marc and everyone at Renovia as we leverage our pipeline of digital therapeutic and diagnostic devices to help create a new standard of care in women’s health.”

Prior to joining Renovia, Mr. O’Connor worked for 12 years at United Technologies Corp. (UTC), a Fortune 100 company, in legal and business roles of increasing responsibility. Mr. O’Connor began his legal career at Testa, Hurwitz & Thibeault, where his practice focused on securities law, mergers and acquisitions and licensing transactions for private and publicly traded technology companies. Mr. O’Connor received his Bachelor of Arts from Boston College and his Juris Doctor from Cornell Law School in 1999

 

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.